Immune cell therapy shows early promise for patients with pancreatic cancer

A nonengineered, multiantigen-specific T-cell therapy was safe, tolerable, and showed signs of clinical activity in patients who had pancreatic adenocarcinoma, according to preliminary results from a phase I clinical trial presented at the AACR special conference on Immune Cell Therapies for Cancer, held July 19–22.

source https://www.lifetechnology.com/blogs/life-technology-news-blog/immune-cell-therapy-shows-early-promise-for-patients-with-pancreatic-cancer